Related Experiment Video
Updated: Aug 4, 2026
08:57
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials
Neurology
|November 1, 1984
Summary
Linoleic acid treatment for multiple sclerosis (MS) showed benefits, particularly for patients with minimal disability at the start. The treatment reduced relapse severity and duration across all patient groups.
Area of Science:
- Neurology
- Clinical Trials
- Nutritional Science
Background:
- Multiple sclerosis (MS) is a chronic neurological disease.
- Treatment outcomes for MS can vary significantly among patients.
- Linoleic acid is a polyunsaturated fatty acid with potential therapeutic roles.
Purpose of the Study:
- To reanalyze data from three double-blind trials of linoleic acid in MS treatment.
- To investigate if patient characteristics influence treatment response.
- To assess the efficacy of linoleic acid in managing MS progression and relapses.
Main Methods:
- Reanalysis of combined data from 87 treated and 85 control patients across three double-blind trials.
- Neurologic assessments conducted over 2.5-year trial periods.
- Statistical analysis to identify relationships between patient characteristics and treatment response.
Main Results:
- Treated patients with minimal or no baseline disability showed a significantly smaller increase in disability compared to controls (p < 0.05).
- Linoleic acid treatment reduced the severity and duration of relapses.
- Treatment benefits were observed across all levels of initial disability and illness duration.
Conclusions:
- Linoleic acid demonstrates a therapeutic effect in multiple sclerosis, especially in patients with early-stage disease.
- Patient characteristics, specifically baseline disability, are important factors in treatment response.
- Further research into linoleic acid as an MS therapy is warranted.
